You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百利天恒(688506.SH):BL-M11D1(CD33-ADC)聯合用藥治療新診斷的急性髓系白血病獲得藥物臨牀試驗批准通知書
格隆匯 04-22 16:22

格隆匯4月22日丨百利天恒(688506.SH)公佈,近日收到國家藥品監督管理局(NMPA)正式批准簽發的《藥物臨牀試驗批准通知書》,公司自主研發的創新生物藥注射用BL-M11D1(CD33-ADC)聯合用藥的藥物臨牀試驗獲得批准。BL-M11D1是與BL-B01D1出自同一技術平台、與BL-B01D1共享同一“連接子+毒素”平台的靶向CD33的ADC藥物。截至目前,除本次新獲得批准的臨牀試驗外,BL-M11D1正在國內進行Ib期臨牀試驗,並在美國同步進行I期臨牀試驗,適應症為復發或難治性急性髓系白血病(r/rAML)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account